 Patients receive pomalidomide orally PO on days 1-21; bortezomib intravenously IV on days 1, 8, and 15; and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. 